A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Dexamethasone (Primary) ; KappaMab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Proof of concept; Therapeutic Use
- 01 Aug 2023 Status changed from active, no longer recruiting to completed according to results published in the British Journal of Haematology.
- 01 Aug 2023 Results published in the British Journal of Haematology
- 29 Jun 2023 Results presented in the HaemaLogiX Media Release.